Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Development and Phase III trial results of levacetylleucine for ataxia-telangiectasia

Michael Leo Strupp • 29 Jun 2026
EAN 2026
Movement Disorders Levacetylleucine

Michael Leo Strupp, MD, FRCP, FANA, FEAN, Ludwig Maximilian University of Munich, Munich, Germany, discusses the development of levacetylleucine for cerebellar diseases, sharing findings from a Phase III (NCT06673056) trial in ataxia-telangiectasia. Prof. Strupp discusses the development of this agent, findings from animal studies, and encouraging data from the Phase III trial. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
2:02
When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
Katarina Rukavina • 29 Jun 2026
What is currently understood about the role of hormonal changes in Parkinson's disease?
2:46
What is currently understood about the role of hormonal changes in Parkinson's disease?
Katarina Rukavina • 29 Jun 2026
Ongoing research into foslevodopa/foscarbidopa in PD treatment
4:47
Ongoing research into foslevodopa/foscarbidopa in PD treatment
K. Ray Chaudhuri • 30 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
13:26
A discussion at EAN 2026 on the impact of climate change on neurological diseases
Amalia Ghergu et al. • 28 Jun 2026
The content of VJNeurology is intended for healthcare professionals